Skip to main content
. Author manuscript; available in PMC: 2015 Jun 2.
Published in final edited form as: Int J Lab Hematol. 2010 Jul 7;32(5):461–476. doi: 10.1111/j.1751-553X.2010.01246.x

Table 5.

Presumptive karyotypic evidence of myelodysplastic syndrome*

Type Cytogenetic abnormalities
Balanced t(11;16)(q23;p13.3), t(3;21)(q26.2;q22.1), t(1;3)(p36.3;q21.2), t(2;11)(p21;q23),
inv(3)(q21q26.2), t(6;9)(p23;q34)
Unbalanced −7 or del(7q), −5 or del(5q), i(17q) or t(17p), −13 or del(13q), del(11q), del(12p) or
t(12p), del(9q), idic(X)(q13)

These cytogenetic abnormalities can be used as presumptive evidence of myelodysplastic syndrome in the setting of persistent cytopenias of undertermined etiology without definite morphologic dysplasia